Sanuwave Health Announces Preliminary Q4 2025 Revenue of $13.3–$13.4 Million, Up 29–30% Year-over-Year; Achieves Record Quarterly and Full-Year Revenue

Core Insights - Sanuwave announced preliminary revenues of $13.3 million to $13.4 million for Q4 2025, marking the highest quarterly revenues in the company's history [1][2] - Q4 2025 revenue increased by 29% to 30% compared to Q4 2024 [1][2] - Full Year 2025 revenue reached $44.3 million to $44.4 million, representing a 36% increase compared to Full Year 2024, setting an all-time record for the company [1][2] Financial Performance - Q4 2025 revenue is expected to be within the guidance range provided in the Q3 2025 earnings release [2] - The company experienced significant growth in revenue, with Q4 2025 revenues being the highest ever recorded [1][3] Market Context - The CEO highlighted that the second half of 2025 was a period of transition in the wound care market due to changes in reimbursement rates, which created opportunities for the company [3] - Sanuwave has been actively acquiring new partners and sales channels to adapt to market changes while maintaining focus on patient needs in advanced wound care [3] Company Overview - Sanuwave Health specializes in the research, development, and commercialization of patented, non-invasive directed energy systems for skin, musculoskeletal tissue, and vascular structure repair and regeneration [4] - The company's portfolio includes regenerative medicine products aimed at restoring normal healing processes across various medical conditions [5]